Clinical Trials Logo
  1. Home
  2. CMV
  3. NCT03502161
  4. Details
NCT03502161 Clinical Trial

Clinical Evaluation of the QuantiFERON CMV Assay

CMV Clinical Trial

Official title:
Clinical Evaluation of the QuantiFERON CMV Assay

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT03502161
Other study ID # C16-CMV-001
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 15, 2018
Est. completion date June 30, 2020

Study information
Verified date September 2020
Source QIAGEN Gaithersburg, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.

Recruitment information / eligibility
Status Terminated
Enrollment 8
Est. completion date June 30, 2020
Est. primary completion date May 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult CMV D+/R- liver, kidney, heart, pancreas, lung, intestinal, or combined transplant recipients that are 18 years of age or older.

- Scheduled to receive between 3 to 6 months of antiviral prophylaxis

- Provide Informed Consent

Exclusion Criteria:

- Subjects less than 18 years old

- Scheduled to receive longer than 6 months or shorter than 3 months of prophylaxis

- Unable to provide Informed Consent

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• QuantiFERON CMV Assay
Assay to measure cell-mediated immune function using QuantiFERON CMV assay.

Locations
Country Name City State
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Sponsors (1)
Lead Sponsor Collaborator
QIAGEN Gaithersburg, Inc

Country where clinical trial is conducted

United States, 

References & Publications (2)

Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis. 2001 Mar 1;32(5):742-51. Epub 2001 Feb 20. Review. — View Citation

Tolkoff-Rubin N, Rubin R. The impact of cytomegalovirus infection on graft function and patient outcome. Graft 1999; 2:S101-3.

Outcome
Type Measure Description Time frame Safety issue
Primary Change in time to CMV Infection between sub-groups of QF-CMV assay classifications. Measurement of QF-CMV result At time of prophylaxis termination, +1 month from termination, +2 months from termination
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04101136 - Effect of Atorvastatin on Subclinical Atherosclerosis N/A
Recruiting NCT06001320 - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip Early Phase 1
Completed NCT01923766 - Cytotoxic T Cells to Prevent Virus Infections Phase 1
Not yet recruiting NCT05969743 - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease Phase 2
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting NCT06034925 - Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients Phase 4
Completed NCT04840199 - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. Phase 2
Not yet recruiting NCT06211543 - Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
Recruiting NCT04056533 - Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy Phase 2
Not yet recruiting NCT04280380 - Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Active, not recruiting NCT03924219 - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Completed NCT02694484 - Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant N/A
Recruiting NCT06011486 - Expansion of Virus-Specific Lymphocytes for Cell Therapy Phase 1
Recruiting NCT04017962 - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection Phase 2
Terminated NCT03570411 - Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
Enrolling by invitation NCT04392297 - Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
Completed NCT00872703 - Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection? N/A
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Recruiting NCT05041426 - Letermovir for CMV Prevention After Lung Transplantation Phase 2
Recruiting NCT03858907 - Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV